AgomAb Therapeutics NV
AGMB Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$8.57
KIRA · Stoqly’s AI analyst, in plain words
- AgomAb Therapeutics NV lost $70.5M in fiscal 2025.
Market cap
$4.6M
P/E
—
Revenue
—
Net income
−$70.5M
Free cash flow
—
Operating margin
—
AgomAb Therapeutics NV in 30 seconds · fiscal 2025
Does it make a profit?
−$70.5M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What AgomAb Therapeutics NV does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 23, 2026
- Legal name
- AgomAb Therapeutics NV
- CIK
- 0002020932
AgomAb Therapeutics NV · AGMB
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$12.3M | −$50.1M | −$70.5M |
| Diluted EPS | −$38.53 | −$115.85 | −$161.50 |
| Cash | |||
| Cash from operations | −$26.6M | −$50.7M | −$58.3M |
| Share count change | — | 0.0% | 0.0% |
| Debt and strength | |||
| Cash and short-term investments | $135M | $178M | $102M |
| Shareholders' equity | $167M | $195M | $154M |
| Current ratio | — | 19.0x | 6.5x |
| Interest coverage | −1,006.8x | −716.5x | −987.3x |
| Returns and quality | |||
| Return on equity | −7.4% | −27.6% | −40.4% |
| Return on tangible equity | −7.4% | −30.2% | −58.7% |
Insiders bought, 12 months
$0.4M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
AgomAb Therapeutics NV · AGMB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $8.57 a share, the company is worth $4.6M.
Source: SEC EDGAR XBRL filings (CIK 0002020932). Data updated October 24, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.